News, Scientific publications and Events

Noventure expands the commercialization of GELSECTAN® across Europe through new partnerships

Noventure is proud to announce new agreements for the distribution of its medical device GELSECTAN® with Klinge (Germany), Tramedico (Benelux), Montavit (Austria), Galenica (Greece, Romania Bulgaria and Cyprus), Lapidot (Israel) and Sabora (Finland). These partnerships come after the successful partnership with Norgine in Spain and Portugal, where GELSECTAN® is already on the market. Irritable bowel syndrome is a burdensome disease which has an estimated global prevalence of more than 10%, predominantly affecting adults, especially women, of working age.

Gastroenterology Pediatrics News TASECTAN®

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia, Adiarin® has been granted local marketing authorization as class II medical device.

Allergology / ent Barrier Technology Gastroenterology Pediatrics Uro-ginecology Scientific Publication UTIPRO® PLUS GELSECTAN® RHINOSECTAN® XILAPLUS®

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Núria Piqué, María del Carmen Gómez-Guillén and María Pilar Montero

Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic.

You are here

Magazine

Noventure expands the commercialization of GELSECTAN® across Europe through new partnerships

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Let's meet in..

Magazine

Noventure expands the commercialization of GELSECTAN® across Europe through new partnerships

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Pages

Let's meet in..